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Abstract 
Background: Fluid resuscitation is frequently required for cardiac surgical patients 
admitted to the intensive care unit. The ideal fluid of choice in regard to efficacy and 
safety remains uncertain. Compared with crystalloid fluid, colloid fluid may result in less 
positive fluid balance. However, some synthetic colloids are associated with increased 
risk of acute kidney injury (AKI). This study compared the effects of succinylated gelatin 
(4%) (GEL) with compound sodium lactate (CSL) on urinary AKI biomarkers in patients 
after cardiac surgery.
Methods: Cardiac surgical patients who required an intravenous fluid bolus of at 
least 500 mL postoperatively were randomly allocated to receive GEL or CSL as the 
resuscitation fluid of choice for the subsequent 24 h. Primary outcomes were serial 
urinary neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C concentra-
tions measured at baseline, 1 h, 5 h and 24 h after enrolment, with higher concentra-
tions indicating greater kidney injury. Secondary biomarker outcomes included urinary 
clusterin, α1-microglobulin and  F2-isoprostanes concentrations. Differences in change 
of biomarker concentration between the two groups over time were compared with 
mixed-effects regression models. Statistical significance was set at P < 0.05.
Results: Forty cardiac surgical patients (n = 20 per group) with similar baseline char-
acteristics were included. There was no significant difference in the median volume of 
fluid boluses administered over 24 h between the GEL (1250 mL, Q1–Q3 500–1750) 
and CSL group (1000 mL, Q1–Q3 500–1375) (P = 0.42). There was a significantly 
greater increase in urinary cystatin C (P < 0.001), clusterin (P < 0.001), α1-microglobulin 
(P < 0.001) and  F2-isoprostanes (P = 0.020) concentrations over time in the GEL group, 
compared to the CSL group. Change in urinary NGAL concentration (P = 0.68) over 
time was not significantly different between the groups. The results were not modified 
by adjustment for either urinary osmolality or EuroSCORE II predicted risk of mortality.
Conclusions: This preliminary randomised controlled trial showed that use of suc-
cinylated gelatin (4%) for fluid resuscitation after cardiac surgery was associated with 
increased biomarker concentrations of renal tubular injury and dysfunction, compared 
to crystalloid fluid. These results generate concern that use of intravenous gelatin fluid 
may contribute to clinically relevant postoperative AKI.
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Background
Optimising cardiac preload with intravenous fluid boluses is frequently required in car-
diac surgical patients admitted to the intensive care unit (ICU). However, positive fluid 
balance and fluid overload are associated with adverse patient outcomes [1, 2], and 
the ideal fluid remains uncertain. Compared with crystalloids, there is some evidence 
that synthetic colloids provide both greater volume expansion and cardiac output, and 
a less positive fluid balance [3–5], and that these perceived benefits influence reported 
practice [6]. Conversely, the safety of some types of colloid fluid such as hydroxyethyl 
starch remains a concern, including their potential to induce or exacerbate acute kidney 
injury (AKI) [7]. Diversion of clinical practice away from hydroxyethyl starch may have 
increased use of gelatin colloids in some cardiac surgical centres [8], despite a lack of 
efficacy and safety data on gelatin colloids from large randomised controlled trials.
Patients undergoing cardiac surgery are at high risk of postoperative AKI [9], a major 
cause of increased morbidity and mortality. As such, using an intravenous fluid that 
is safe for the kidney is pivotal for these patients. Recent observational data suggest 
that gelatin fluid may induce or exacerbate renal injury [10, 11]. Animal models have 
shown that gelatin fluid causes renal tubular epithelial vacuolation, or vesiculation, and 
an increase in biomarkers of AKI including neutrophil gelatinase-associated lipocalin 
(NGAL) and cystatin C [12–14]. These biomarkers are associated with clinically signifi-
cant AKI in patients after cardiac surgery [15–17]. Furthermore, gelatin fluid induces 
platelet dysfunction and reduces clot strength [18–20], which is particularly important 
for patients undergoing cardiac surgery. Given these potential adverse effects, it is cur-
rently unclear if administration of gelatin fluid results in overall benefit or harm.
In this randomised controlled trial, we compared the effects of succinylated gelatin 
(4%) (GEL) (Gelofusine™, B. Braun Australia Pty Ltd) on a range of urinary AKI bio-
markers, compared to a balanced crystalloid solution, compound sodium lactate (CSL), 
in patients who had undergone major cardiac surgery. We hypothesised that fluid bolus 
therapy with CSL would be associated with a lesser increase in concentrations of uri-
nary NGAL and cystatin C over time, compared to GEL. Secondary outcomes included 




The GELATIne Fluid and Acute Kidney Injury in Critical Illness (GELATI) Trial was an 
investigator-initiated, single-centre, randomised, open-label, parallel-arm designed clin-
ical trial. Approval was obtained from the South Metropolitan Health Service Human 
Research Ethics Committee (RGS0000000105; 31st August, 2017), and registration with 
the Australian and New Zealand Clinical Trials Registry (ACTRN12617001461381; 16th 
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October, 2017) before commencement. After obtaining written informed consent prior 
to surgery, 40 participants (20 in each group) were enrolled and randomly allocated to 
receive either GEL or CSL for fluid boluses after cardiac surgery in the 30-bed ICU of 
the Fiona Stanley Hospital in Perth, Western Australia.
After postoperative admission to the ICU, consented patients were screened again 
by a study investigator, in conjunction with the ICU clinician. Eligible patients were 
those for whom the treating ICU clinician intended to administer an intravenous fluid 
bolus of 500 mL or more within 60 min, and in whom they believed there was equipoise 
in using either GEL or CSL. The exclusion criteria were: < 18  years old; serum creati-
nine > 265 µmol  L−1 prior to surgery; end-stage renal failure requiring dialysis; urine out-
put < 10 mL  h−1 over the previous 4 h; severe AKI requiring renal replacement therapy 
(RRT), or likely to require RRT within the next 24  h; known allergy to GEL; received 
GEL in the previous 48 h; admitted to ICU for longer than 96 h; previously enrolled in 
the study; a limitation of care order had been placed; death was perceived to be immi-
nent; or the treating clinician perceived that participation in the study was not in the 
patient’s best interests. The serum creatinine concentration limit of 265  µmol  L−1, or 
3 mg  dL−1, corresponded with an estimated creatinine clearance of < 30 mL/min for the 
anticipated demographic, consistent with severe chronic renal insufficiency [21].
Intraoperative management was conducted according to local standard practice. All 
participants received routine monitoring including 5-lead electrocardiogram, systemic 
arterial and central venous pressure monitoring. Pulmonary artery catheterisation was 
performed at the treating anaesthetist’s discretion. For participants receiving cardio-
pulmonary bypass (CPB), 2  g of tranexamic acid was administered as an intravenous 
infusion, commencing after induction, and heparin was dosed to achieve an activated 
clotting time (ACT) of > 480  s. CPB circuits were primed with 1600  mL of balanced 
isotonic crystalloid fluid (Plasmalyte A; Baxter Healthcare, Phoenixville, PA, USA). 
Following CPB, heparin was reversed with protamine targeting an ACT of < 130 s. For 
participants not receiving CPB, administration of drugs was similar except that target 
ACT was > 300 s during heparinisation and < 150 s post-reversal. Fluid management in 
the operating theatre consisted of blood products and balanced isotonic crystalloid, as 
required, but no synthetic colloid fluid.
Randomisation and blinding
Patients were randomly allocated to receive intravenous fluid bolus therapy with either 
GEL or CSL. Randomisation was performed via block design of 4 blocks of 10 partici-
pants each (5 in each treatment arm) generated by an online random number genera-
tor 1. Allocation concealment was achieved by sealed, opaque, sequential numbered 
envelopes prepared by a scientist not involved with the study. Once a participant was 
enrolled, either a member of clinical staff or study investigator opened the next available 
envelope to reveal treatment allocation. The administration of study fluid was open label 
for reasons of feasibility, but primary outcome assessment was blinded to clinical staff.
1 www. rando mizer. org; accessed on the 5th November, 2018.
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Interventions
Participants were randomised to receive an initial study fluid bolus of at least 500 mL. 
Fluid delivery started as soon as a baseline urine sample had been collected. Fur-
ther boluses of the assigned study fluid were administered if considered clinically 
indicated by the treating clinician. After administering a total study fluid volume of 
50  mL   kg−1 or 3000  mL, or 24  h after randomisation, whichever occurred first, the 
choice of further fluid therapy was at the discretion of the treating clinician. The use 
of more than 50 mL  kg−1 or 3000 mL of GEL was strongly discouraged. Use of other 
fluids during the intraoperative and postoperative period, including crystalloid for 
maintenance fluid requirements or drug administration, and blood products includ-
ing human albumin solution, was at the discretion of the treating clinicians.
Outcomes and analytic techniques
The primary outcome was urinary NGAL and cystatin C concentrations over time up 
to 24 h post-randomisation. Secondary outcomes included other biomarkers of AKI: 
urinary clusterin, α1-microglobulin and  F2-isoprostanes concentrations. Urine col-
lection occurred immediately after randomisation (T0), then at 1 (T1), 5 (T5) and 
24 (T24) hours after the start of the first fluid bolus. Details of the sample collec-
tion methods are provided in Additional file 1. Urinary NGAL, cystatin C, clusterin 
and α1-microglobulin were measured using a commercial multiplex magnetic bead 
array (Milliplex Human Renal Toxicity Panel, MilliporeSigma, Burlington, MA, USA) 
according to manufacturer’s instructions. Urine  F2-isoprostanes concentration, which 
indicates induced oxidative stress, was measured by gas chromatography–mass spec-
trometry (Agilent 6890N gas chromatograph coupled to an Agilent 5975B mass spec-
trometer) using electron capture negative ionisation and selective ion monitoring. 
Urine osmolality was measured by freezing point depression (Osmometer Type 6 M, 
Löser Messtechnik, Berlin, Germany). Urine creatinine concentration was measured 
using a commercial analyser (COBAS INTEGRA 400 plus, Roche Diagnostics, Basel, 
Switzerland).
The following clinical outcomes were also recorded in this study: maximum AKI 
stage within the first 7 days, RRT-free days within the first 28 days, number of blood 
product units transfused during the ICU stay, ICU-free days within 28  days, and 
60-day all-cause mortality. Clinical data collection details are described in Additional 
file 1.
Statistical methods
Sample size calculation was based on the clinically important difference in NGAL 
that has been reported to be associated with AKI in a critically ill population. 
Patients with burn injury and early AKI had an approximately twofold increase in 
urine NGAL concentration within 48 h after admission, compared to those without 
AKI [22]. Extrapolating the means and standard deviations from the data provided 
in this study (AKI: 240 ± 76 ng/mL; no AKI: 140 ± 38 ng/mL), a sample size of 5 in 
each arm would give 80% power (α = 0.05) to detect a twofold difference in NGAL. A 
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conservative sample size of 20 per arm (total 40 patients) was planned to reduce the 
risk of type II error, which would detect a mean difference in NGAL > 55  ng.mL−1 
between the two groups with a power of 80%.
Normality of data was assessed by visual inspection of histograms and Q–Q plots. 
Data are presented in median and first to third quartiles (Q1–Q3) or counts and per-
centages, as appropriate. Inferential tests were not applied to baseline characteris-
tics, in line with the 2010 CONSORT statement [23]. Total study fluid volumes were 
compared using Wilcoxon rank sum test. Biomarker concentrations were log-trans-
formed to produce normal or approximately normal distributions. Comparisons of 
change in biomarker concentration over time were made using linear mixed-effects 
models. Models were bootstrapped to obtain robust P values for biomarkers that 
remained slightly skewed following log transformation. P values are presented for 
the interaction between treatment and time in the unadjusted model. Biomarker 
concentrations were summarised as predicted mean (95% confidence interval) esti-
mated by the unadjusted models. A Bonferroni-corrected P value significance cut-off 
of < 0.01 for each linear mixed-effects model was further applied in order to reduce 
Type I error created by multiple biomarker analyses. The effects of urine concentra-
tion, as osmolality, and illness severity, as estimated by EuroSCORE II mortality pre-
diction [24], were also assessed as potential confounders.
Clinical outcomes were compared using Fisher’s exact test for categorical variables 
or Wilcoxon rank sum test for non-normal continuous data. Ventilation time was 
compared using negative binomial regression due to the nature of its distribution. 
No adjustment was applied to account for multiple comparisons in the exploratory 
analyses of clinical outcomes.
Analyses were performed using Stata 14 (College Station, TX, USA) and SAS (SAS 
Institute, Cary, NC, USA) with significance set at two-sided P < 0.05, except for Bon-
ferroni correction where stated.
Results
Participant characteristics
Of the 81 participants screened for eligibility between December, 2018 and February, 
2019, 40 participants (n = 20 per study arm) were enrolled and randomised (Fig. 1). 
Baseline characteristics were similar between the two groups (Table  1). The total 
volume of study fluid administered during the study period was not significantly dif-
ferent between the two groups (P = 0.42) (Table  2). No participants received more 
than a total of 2500 mL of study fluid. Three participants (two in the GEL group and 
one in the CSL group) received a single bolus of crystalloid in the ICU before study 
enrolment. One participant in the GEL group returned to the operating theatre and 
received a crystalloid bolus during reoperation between T1 and T5. No participants 
in the CSL group received GEL during their entire ICU stay. Thirty-eight out of 40 
participants had their urine samples collected per protocol; in one participant, the 
T1 urine sample was delayed by 1 h and, in another participant, the T24 sample was 
delayed by four hours.
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Serial changes in AKI biomarkers
Of the five urinary biomarkers analysed, there was a significantly greater increase over 
time for cystatin C (P < 0.001), clusterin (P < 0.001), α1-microglobulin (P < 0.001) and 
 F2-isoprostanes (P = 0.020) concentrations in the GEL group, compared to the CSL group 
(Fig. 2). The differences between groups for cystatin C, clusterin and α1-microglobulin 
remained significant after adjusting for multiple comparisons. There was no significant 
difference in change of NGAL concentration over time between groups (P = 0.68). The 
overall result for each biomarker was not modified by adjustment for urine osmolality 
and there was no association detected between biomarker concentrations and Euro-
SCORE II predicted risks of mortality. Results of the linear mixed-effects model analy-
sis for the primary outcomes, both unadjusted and adjusted for osmolality, are provided 
in Additional file 2. Urine concentration and output are also described in Figure, Addi-
tional file 3.
Clinical outcomes
According to rises in plasma creatinine during the study period, 13 participants devel-
oped clinical AKI during the first 7  days of hospitalisation (five in the GEL group, 
eight in the CSL group) (P = 0.73) (Table  3). Biomarker concentrations stratified by 
clinical AKI were explored post hoc and are provided in Additional file 4. No patients 
required RRT within 28 days. The median fluid balance between T0 and T24 was not 
Fig. 1 Study CONSORT flowchart
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significantly different between the two groups (GEL: 1751  mL (872–3022) vs CSL: 
1261 mL (688–2214)) (P = 0.27). However, there were more participants in the GEL 
group that received packed red blood cell transfusions, compared to the CSL group 
(5 in the GEL group, none in the CSL group) (P = 0.047). The other clinical outcomes 
were not significantly different between the two groups (Table 3).
Discussion
This randomised controlled trial showed that using intravenous gelatin for fluid 
resuscitation, instead of crystalloid fluid, after cardiac surgery was associated with a 
significantly greater increase in urinary biomarkers of AKI over time. These results 
Table 1 Characteristics of cardiac surgical patients who were randomised to receive either 
succinylated gelatin (4%) (GEL) or compound sodium lactate (CSL) as resuscitation fluid after cardiac 
surgery
Data are presented as either median (Q1–Q3) or number (percentage). *Sample size differs to heading of columns. ** Time 
from ICU admission to randomisation
CABG, coronary artery bypass graft; CPB, cardiopulmonary bypass; NYHA, New York Heart Association; LVEF, left ventricular 
ejection fraction
Characteristic GEL (n = 20) CSL (n = 20)
Age (years) 67 (59–70) 68 (58–72)
Male, n (%) 14 (70) 17 (85)
Body weight (kg) 82 (72–97) 81 (70–96)
NYHA class, n (%)
 1 12 (60) 13 (65)
 2 3 (15) 5 (25)
 3 5 (25) 2 (10)
LVEF (%) 56 (46–63) 60 (45–63)
Preoperative serum creatinine concentration (μmol/L) 76 (70–93) 82 (65–98)
Procedure type, n (%)
 CABG 11 (55) 14 (70)
 Valve replacement 5 (25) 4 (20)
 Other 4 (20) 2 (10)
EuroSCORE II mortality predicted risk (%) 1.24 (0.79–1.82) 1.03 (0.82–1.95)
CPB, n (%) 15 (75) 14 (70)
 Pump time (mins)* 103 (82–144) 98 (76–110)
 Cross clamp time (mins)* 86 (47–122) 55 (47–75)
Time-to-enrol** (mins) 75 (36–266) 114 (41–391)
 Urine output at enrolment (mL/kg/h) 0.6 (0.3–1.7) 0.8 (0.3–1.5)
Table 2 Median (Q1–Q3) volumes of study fluid (mL) delivered to cardiac surgical patients who 
were randomised to receive succinylated gelatin (4%) (GEL) or compound sodium lactate (CSL) as 
fluid resuscitation therapy after cardiac surgery between different urine sampling time points
a Difference between treatment groups in total volume of fluid given during study period (Wilcoxon rank-sum test)
Outcome T0–T1 T1–T5 T5–T24 Total P  valuea
Fluid volume (mL)
 GEL 500 (500–500) 125 (0–500) 250 (0–1000) 1250 (500–1750)
 CSL 500 (500–500) 125 (0–500) 250 (0–500) 1000 (500–1375) 0.42
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Fig. 2 Urinary biomarker concentrations (predicted mean, 95% confidence interval) neutrophil 
gelatinase-associated lipocalin (NGAL) (a), cystatin C (b), clusterin (c), α1-microglobulin (d) and 
 F2-isoprostanes (e) of cardiac surgical patients who were randomised to receive either succinylated gelatine 
(4%) (closed circles) or compound sodium lactate (open circles) as fluid resuscitation therapy after cardiac 
surgery. Urine was sampled before the intervention (0 h), then 1, 5 and 24 h later
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are concerning as to the safety of gelatin fluid, with potential adverse clinical implica-
tions for its use, and require further discussion.
There is a strong biological rationale that urinary AKI biomarkers may be more sensi-
tive for detecting AKI than a rise in plasma creatinine, which defines clinically detect-
able AKI. Cystatin C and α1-microglobulin are low molecular weight proteins that are 
freely filtered and reabsorbed in the proximal tubule. Therefore, their elevation in urine 
is expected in the early stages of proximal tubular dysfunction [25–27]. Both of these 
biomarkers measured postoperatively are associated with development of clinical AKI 
in cardiac surgical patients [17, 28]. Clusterin expression is upregulated in both proximal 
and distal tubules after cellular injury [29, 30], therefore it is also expected to increase in 
the urine, even with mild AKI. Finally,  F2-isoprostanes are a marker of cellular oxidative 
injury and an elevation in urine concentration suggests renal oxidative stress [31]. As 
such, increases in urinary concentrations of these four biomarkers in patients who had 
received gelatin are concerning and may represent clinically relevant kidney injury.
We did not observe any differences in urinary NGAL concentration between the two 
groups. NGAL is a protein rapidly produced by both the proximal and distal renal tubu-
lar epithelial cells in response to ischaemia and drug-induced injury [26, 32]. Over a 
30-fold increase in urinary NGAL was observed after gelatin in a canine haemorrhagic 
shock model [14] and this effect was also observed in a rodent sepsis model [12]. It is 
possible that there is a species difference in either susceptibility to gelatin-induced renal 
injury or stimulation of NGAL production by gelatin. For the latter mechanism, gelatin is 
rapidly degraded by gelatinase conjugated to the heterodimeric form of NGAL [33, 34], 
but it is unclear if provision of the substrate itself (i.e. gelatin) can stimulate production 
Table 3 Clinical outcomes of cardiac surgical patients who were randomised to receive 
succinylated gelatin (4%) (GEL) or compound sodium lactate (CSL) as fluid resuscitation therapy after 
cardiac surgery
Data are presented as either median (Q1–Q3) or number of patients (percentage of group). * KDIGO stage was calculated as 
maximum change in plasma creatinine within 7 days of randomisation. **P values have been rounded to two decimal places
ICU, intensive care unit; KDIGO, Kidney Disease Outcomes Kidney Disease: Improving Global Outcomes; RRT, renal 
replacement therapy
Outcome GEL (n = 20) CSL (n = 20) P value**
KDIGO stage*, n (%) 0.73
 Stage I 4 (20) 7 (35) –
 Stage II 1 (5) 1 (5) –
 Stage III 0 0 –
28-day RRT-free days 28 (28–28) 28 (28–28) N/A
Chest drain output (mL) 485 (344–687) 335 (268–428) 0.05
Received blood products, n (%)
 Packed red blood cells 5 (25) 0 (0) 0.05
 Cryoprecipitate 1 (5) 0 (0) N/A
 Platelet concentrate 1 (5) 0 (0) N/A
Received albumin, n (%) 2 (10) 2 (10) N/A
Return to theatre, n (%) 3 (15) 0 (0) 0.23
Ventilation time (hours) 17 (11–30) 11 (10–15) 0.06
Fluid balance (mL) 1751 (872–3022) 1261 (688–2214) 0.27
28-day ICU-free-days 26 (24–27) 26 (24–27) 0.60
60-day mortality, n (%) 0 (0) 0 (0) N/A
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of NGAL in the kidney. Although we did not observe a large increase in urinary NGAL 
after GEL in this study, compared to CSL, there was a rise in NGAL within hours in both 
groups over time (Additional file 2), which is consistent with other cardiac surgical stud-
ies [28, 35–38]. It has been shown that all forms of NGAL are present postoperatively 
in cardiac surgical patients [39], therefore any effect of GEL on a certain specific form 
of NGAL may have been obscured by increases in other types of NGAL. In addition, 
the presence of gelatin itself in the urine may have interfered with the NGAL assay [40], 
which may have masked elevations of this biomarker in either group.
Clinical AKI as defined by a substantial rise in plasma creatinine concentration occur-
ring in approximately one-third of participants, with the majority of events being stage 
1. This proportion of participants experiencing AKI is consistent with previous studies 
reporting on similar cohorts [15–17]. Though this event was transient for most, even 
small-to-moderate increases in creatinine may have adverse consequences for cardiac 
surgical patients [41], including increased resource utilisation 2. We were interested in 
associations between increased biomarker concentrations and the presence of clinical 
AKI in this study, which were explored post hoc (Additional file 4); however, an inad-
equate sample size of patients with clinical AKI precluded any definitive inference. For 
patients who do not experience a postoperative rise in plasma creatinine, there may still 
be adverse renal sequelae. Evidence shows that a proportion of patients undergoing car-
diac surgery will have sub-clinical AKI, with elevated urinary biomarkers paired with a 
lack of rise in plasma creatinine concentration, and only manifested with a subsequent 
loss of renal functional reserve [42]. Despite being unable to establish the clinical impor-
tance of the rise in biomarker concentrations seen in this study, the potential exacerba-
tion of AKI by use of gelatin fluid presents a major public health issue, especially given 
the burden of AKI on morbidity and mortality of cardiac surgical patients. This study 
provides rationale that further investigation assessing the safety and effectiveness of 
intravenous gelatin fluid is required.
We noted that participants who received gelatin were more likely to require packed 
red blood cell transfusion, compared to those who had received crystalloid fluid alone. 
This may well represent a chance finding, but gelatin’s deleterious effects on clot forma-
tion could also explain this, in part [18–20]. This finding also supports the results of a 
recent observational trial in cardiac surgical patients, whereby administration of gela-
tin was associated with increased chest drain output, bleeding events and red blood cell 
transfusion, compared to crystalloid fluid alone [43]. The effect of gelatin on coagulation 
and bleeding remains contentious [44], and this deserves further investigation.
This study has some limitations. Lack of blinding of the study fluid to treating clini-
cians may have affected treatment decisions, though we did not detect any differences 
in the volume of study fluid administered between groups and no clinicians withdrew 
their patients from the study after randomisation. We did not measure urinary albumin 
concentrations in our participants. Albuminuria secondary to glomerular damage may 
have caused other functional markers to increase, such as cystatin C, due to competi-
tion for tubular uptake [45]. Urine samples were allowed to dwell at room temperature 
2 ANZSCTS Cardiac Surgery Database Program National Annual Report 2018.
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in the urinary collection bag for 1 to 4 h before collection. However, the dwell time was 
unlikely to confound the results of this trial given the sampling protocol fidelity and the 
chemical stability of these biomarkers under various storage conditions [46–48]. Uri-
nary biomarkers were not indexed to total urine volume, therefore absolute biomarker 
concentrations may have been affected by tubular flow rate. It was not considered fea-
sible to align measurement of urine volume, as needed for patient care, with study time 
points. Adjusted analysis and further data pertaining to urine concentration and volume, 
available in the Additional files, did not suggest that this was important in explaining 
our results. Finally, subtle baseline imbalances in participant characteristics in this ran-
domised trial may have introduced some degree of confounding to our results. Nonethe-
less, our a priori statistical analysis plan was robust by comparing the serial changes in 
biomarker concentrations while adjusting for any differences in baseline concentrations. 
Furthermore, our results remained unchanged after adjustment for severity of illness, as 
estimated by the predicted risk of mortality.
In conclusion, this randomised controlled trial showed that use of succinylated gelatin 
(4%) for fluid resuscitation after cardiac surgery was associated with an increase in some 
biomarkers of renal tubular injury and dysfunction within 24  h, compared to crystal-
loid fluid. These results support the concern that use of gelatin fluid may be associated 
with increasing the risk of post-operative AKI. There was a signal, albeit still limited, that 
succinylated gelatin (4%) may affect bleeding tendency. Given that succinylated gelatin 
(4%) is more expensive than crystalloid fluid, an adequately powered randomised con-
trolled trial focused on clinical outcomes is needed to confirm its safety in cardiac surgi-
cal patients.
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